Update: Accelerated development
We raise our Abzena valuation to £105m (108p/share) following partner Gilead’s plans to accelerate the development of antibody GS-5745, with Phase III (gastric cancer) and Phase II/III (ulcerative colitis) studies to start in H215. Eight antibodies are currently in clinical development using Abzena’s technology, and more are expected to enter the clinic in the next 12-24 months. Abzena could receive small royalties on these products (and others such as antibody-drug conjugates, ADCs), which offer the prospect of substantial future revenues.Abzena is providing a range of complementary services and technologies for the selection, development and manufacture of biopharmaceuticals.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.